A trial fibrillation (AF) raises the risk of stroke 5-fold, and long-term anticoagulant therapy can reverse this risk. 1, 2 Previous analyses indicate that paroxysmal AF poses a risk of stroke comparable to sustained AF. As a result, guidelines use the same criteria for recommending long-term anticoagulation for patients with paroxysmal AF as for patients with permanent AF. 3-5 However, paroxysmal AF in these studies was clinically diagnosed and generally represented a substantial burden of AF. Recent analyses from clinical trials report a modestly reduced risk of stroke with paroxysmal AF when compared with persistent or permanent AF. 6 Presumably, at some low frequency and duration of AF episodes, the risk of stroke diminishes toward the stroke risk of patients in persistent sinus rhythm. Studies of patients with cardiac implantable electronic devices (CIED) with continuous monitoring capability indicate that several hours of AF and even shorter episodes convey substantial stroke risk. 7,8 However, these data are difficult to collect prospectively, and studies have been limited by having only a small number of relevant stroke events. We assembled a larger number of such stroke events by linking electronic medical record, administrative, and CIED continuous remote monitoring data from all patients in the Veterans Affairs Health Care System (VA). We analyzed these data using a case-crossover study design, which allowed us to efficiently assess increased stroke risk because of AF burden, while controlling for chronic patient features that affect stroke risk. 9
created by linking 2 data sources: (1) administrative and electronic medical record data from the VA; (2) remote monitoring enrollment and daily AF burden data from the CIED device manufacturer (Medtronic Inc, Mounds View, MN). The VA has maintained a centralized program, the VA National Cardiac Device Surveillance Program, for all CIED remote monitoring since 2002. 10 The program has provided remote monitoring and surveillance for >31 000 devices. 10 Patients receiving CIED implants in the VA are voluntarily enrolled in remote monitoring, and 65% of devices implanted in the VA are enrolled. Linkage was limited to a single device manufacturer for 2 reasons: (1) day-level AF burden data were not available in most CIEDs from other manufacturers during the observation period and (2) the selected manufacturer represents the majority of CIEDs followed by the VA (67%) during the observation period.
We first identified VA patients with a Medtronic CIED, who were enrolled in remote monitoring with VA National Cardiac Device Surveillance Program between July 12, 2002, and April 30, 2012. Analysis was restricted to pacemakers and implanted cardioverter defibrillators (ICDs) with atrial leads that were capable of transmitting day-level AF burden data. Data fields included implant date, device lead and model numbers, remote monitoring enrollment (activation, termination, and last transmission), and daily AF burden.
We then linked patient data from VA inpatient, outpatient, pharmacy, and medical claims data sources from the same time period. Linked and merged data sets include the following 11 : (1) the VA National Patient Care Database, which contains outpatient, inpatient, and longterm care administrative data; (2) the VA Decision Support System national pharmacy extract, which contains patient-level detail on medication, dispensing details, and cost; (3) the VA Fee Basis Inpatient and Outpatient data sets, which capture non-VA care provided to veterans; (4) the Veterans Health Administration Vital Status File, which contains validated combined mortality and demographic data from VA, Medicare, and Social Security Administration sources; and (5) Medicare Part A and B data, which include inpatient and outpatient claims for care administered under Medicare benefits. [11] [12] [13] Device data were deterministically linked by applying an identification-deidentification crosswalk from the real medical record number to a scrambled medical record number used in VA and Medicare administrative files. Linked records were additionally required to match on sex and on 2 of 3 date of birth components (month, day, and year). 14 From these linked data sets, we identified patients with acute stroke from inpatient International Classification of Diseases-Ninth Revision (ICD-9) codes listed in the primary discharge position using VA and Medicare inpatient claims ( Table I in the Data  Supplement) . 15, 16 The index date of stroke was defined as the date of admission for the event. We excluded patients who did not have 120 days of continuous remote monitoring on and before the index stroke event. Cohort assembly is detailed in Figure 1 .
Monitoring devices recorded daily duration of AF, defined as the amount of time during a 24-hour daily period that the patient meets programmed AF detection criteria. This measure of daily AF burden can include multiple episodes of AF on a given day. Evidence of AF episodes is accumulated based on the number and timing of atrial events between ventricular intervals. At least 2 atrial sensed events must occur per ventricular interval for 32 ventricular intervals, and the median of the 12 most recent sensed atrial intervals must be shorter than that of the programmed AF detection interval (nominally 350 ms). The devices in this study used AF detection algorithms that have been evaluated extensively and have been shown to quantify AF burden with 99% accuracy. [17] [18] [19] Baseline comorbidities, such as previous medical documentation of AF, were ascertained by validated and previously used ICD-9-based algorithms in the 729 days (2 years) before the index event and not counting the index stroke event. 13 CHADS 2 and CHA 2 DS 2 -VASc scores were calculated using published algorithms combining component comorbidities. 12, 20, 21 Anticoagulation (warfarin use) was ascertained by evidence of a dispensed prescription whose days supply covered the date of stroke, or for the control periods, day 91 before the stroke. 13
Case-Crossover Design
In a case-crossover analysis, the immediate pre-event exposure history of an individual patient sustaining an event is compared with the same individual's exposure history during a separate time period that does not include an event. 9 As a consequence, all stable confounders are matched. The case-crossover analysis is appropriate for assessing time-varying exposures that have a transient effect on outcome with a brief latent period. In our primary analysis, we compared AF burden in the 30 days immediately preceding the patient's ischemic stroke (acute stroke case period, days 1-30) with the patient's AF burden in earlier 30-day periods (prestroke control periods, eg, 91-120 days before the stroke). We used the 30-day period immediately preceding the stroke event as the case period based on the assumption that AFinduced cardiac thrombi >30 days are unlikely to embolize and cause stroke (because of dissolution or fibrosis). Choice of the appropriate control periods involves a trade-off between being too proximate such that AF burden in the 2 periods might be correlated and being too distant such that the patient's background status has changed.
WHAT IS KNOWN
• Implanted devices capable of continuous heart rhythm monitoring frequently detect transient episodes of atrial fibrillation (AF).
• Most patients with implanted devices who experience ischemic stroke do not have AF immediately preceding the stroke, leading to speculation that AF does not directly increase stroke risk.
WHAT THE STUDY ADDS
• In a large cohort with implanted devices, multiple hours of device-detected AF on any given day acutely raised the risk of ischemic stroke.
• This risk was transient, dissipating rapidly over the weeks after the end of the AF episode.
• These findings suggest a potential role for novel anticoagulation strategies in patients with episodic AF. We defined AF burden as the maximum total duration of AF on any given day during a given period of time. In our primary analysis, we defined positive AF burden as AF occurring for ≥5.5 hours on any day during a defined 30-day period. This prespecified amount of AF was based on the results of the TRENDS study, which found that a day with ≥5.5 hours of AF burden within a 30-day period doubled the risk of stroke. 7
Statistical Analysis
We compared case versus control periods using matched analyses for dichotomous outcomes, which generated odds ratios (ORs) with confidence intervals (CIs) and P values. These analyses were generalized using conditional logistic regression, adjusting for warfarin use in the case and control periods. In our primary analysis, we assessed the OR for stroke of AF burden ≥5.5 hours with days 1 to 30 before the stroke serving as our case period and days 91 to 120 before the stroke serving as our control period. To add generalizability and statistical power, we also contrasted the case period to 3 control periods (ie, days 31-60, 61-90, and 91-120 before stroke [3:1 matched design]). In subsequent analyses, we varied the threshold for our definition of AF burden, from 30 minutes to 6 hours (in 30-minute increments) of AF on any given day in both case and control periods. In additional analyses, we defined AF burden for 5-day periods and varied the proximity of AF burden to the stroke event date (ie, 1-5, 6-10, 11-15, …, 55-60 days) when compared with 6 fixed control intervals distant from the stroke event date (days 91-95, 96-100, …, 116-120 before the stroke) producing a 6:1 matched analysis. This last analysis addressed how long after an episode of AF the risk of stroke was increased. The project, including patient reidentification, issuing of the crosswalk, and waiver of consent, was approved by the local institutional review board and Palo Alto VA Research & Development Committee.
Results
Of 10 011 Medtronic remote monitoring and CIED registrations for VA patients of devices having atrial leads, there were 9850 patients with 22 023 person-years of follow-up that were matched to VA or Medicare claims data ( Figure 1 ). Of these 9850 patients, 360 patients had a discharge diagnosis consistent with acute ischemic stroke between 2003 and 2013, corresponding to an incidence rate of 1.63 strokes per 100 person-years. Of these 360 patients with stroke, 187 (52%) had at least 120 days of continuous monitoring before the stroke event.
At the time of stroke, the mean age was 68±8.4 years, CHADS 2 score 3.2±1.5, CHA 2 DS 2 -VASc score 4.8±1.7 (not counting the index stroke in the score; Table 1 ). Almost all patients had an ICD (98%), and 2% had a pacemaker. Among all 9850 linked patients (including those without stroke), 93.8% had ICDs, 5.3% had pacemakers, and 0.9% had implantable loop recorders; no patients with implantable loop recorders in this cohort had evidence of a stroke.
Thirty-nine percent of patients with stroke had a diagnosis of AF listed before their event. Warfarin was prescribed for 5.4% of patients at the time of their event, and 19.8% were prescribed warfarin in the initial control period 90 to 120 days before their event (Table 1) .
AF Burden and Odds of Ischemic Stroke
In the 120 days preceding their stroke, 26.2% of patients had ≥6 minutes of AF, 24.6% had ≥1 hour, and 19.3% had ≥5.5 hours on at least 1 day. Using an AF burden cutoff of 5.5 hours, 156 patients (83%) had <5.5 hours on every day in both the case period (1-30 days prior) and the control period (91-120 days prior), and 15 (8%) had ≥5.5 hours of AF on at least 1 day in both 30-day periods. Among the 16 patients with discordant (ie, informative, AF burdens), 13 patients (7%) had ≥5.5 hours of AF recorded on at least 1 day in only the case period as compared with 3 patients (1.6%) in only the control period, 91 to 120 days before the stroke event. This ratio of discordant results confers an unadjusted OR for ischemic stroke of 4.33 (95% CI, 1.19-23.7; Table 2 ). After adjusting for warfarin use, the OR for ischemic stroke associated with an AF burden of ≥5.5 hours remained high at 5.22 (95% CI, 1.22-47.4). To add generalizability and statistical power, we also contrasted the case period to all 3 sequential comparison periods (days 31-60, 61-90, and 91-120), ie, 3:1 matching, resulting in a warfarin-adjusted OR of 4.21 (95% CI, 1.53-13.4).
The 120-day recording of daily hours of AF is displayed in Figure 2 . Figure 2A displays the records for the 13 patients with discordant AF burden who exceeded the AF burden threshold of ≥5.5 hours in the 30-day case period but not in the control period of 91 to 120 days prior. Seven patients had at least 1 day in the case period with 24 hours of AF including 6 with multiple sequential days of 24 hours of AF and 3 with continuous AF throughout the entire 30-day case period. Eleven of these patients had <1 minute of AF in the control period. These 13 patients had a median of 103 (Q1-Q3, 36-405) minutes of AF per day during the case period when compared with a median of 0 (Q1-Q3, 0-0) minutes per day during the control period (Table 3) . By contrast, for the 3 discordant patients who exceeded the AF burden threshold in the control period but not in the case period just before the stroke ( Figure 2B ), 2 had limited periods of AF. For these 3 patients, the median AF burden during the control period was 26 (Q1-Q3, 19-144) minutes per day versus 0 (Q1-Q3, 0-0) minutes per day during the case period. Daily AF records of the remaining 171 who had concordant AF burdens in the case and control periods are shown in Figure 2C and 2D. In the interest of space for Figure 2C , we illustrate a random selection of 10 patients among the 156 patients who did not exceed the AF burden threshold in either the case or the control periods. Among these patients, few had any prolonged episode of AF on any day within the 120 days of observation. The median AF burden was 0 (Q1-Q3, 0-0) minutes per day in both periods. By contrast, the records of the 15 patients who exceeded the AF burden threshold of 5.5 hours in both the case and the control periods ( Figure 2D ) were marked by frequent and prolonged periods of AF, often continuous AF, throughout the observation period. The median AF burden was 1434 (Q1-Q3, 240-1439) minutes per day in the case period and 1438 (Q1-Q3, 71-1439) minutes per day in the control period ( Table 3 ).
Odds of Stroke and Daily Dose of AF
We explored the relationship between odds of stroke and dose of AF by continuously increasing the threshold definition of positive daily AF burden (ie, maximum total duration of AF on any given day in the preceding 30 days) from 30 to 360 minutes. However, our data did not allow clear isolation of the effect of different thresholds because few patients with AF in the case period had short episodes of AF. For example, the OR for stroke with a threshold of ≥30 minutes was 4.04 (95% CI, 1.21-21.2), roughly the same as our prespecified threshold of ≥5.5 hours. 
Odds of Stroke and Temporal Proximity of AF
We assessed the relationship between proximity of AF and odds of stroke by using as our case period 5-day time windows that were increasingly distant from the date of the stroke. We compared the AF burden in each case period (days 1-5, 6-10, …, 56-60 before the stroke) to AF burden in the 6 matched 5-day control periods (days 91-95, 96-100, …, 116-120 before the stroke). In this 6:1 matched analysis, the threshold for AF burden was ≥5.5 hours on any day during the 5-day time window. The risk of stroke was highest within 5 days of the episode of AF (OR, 17.4; 95% CI, 5.4-73.1) and the risk declined steadily with longer periods after the episode of AF, reaching a nadir at ≥30 days (Figure 3 ).
Analyses Using the Subset of More Specific Stroke

ICD-9 Codes
We repeated the analyses on the subgroup of patients with the highly specific set of ICD-9 codes of 434.x1 ( Table I in the Data Supplement). The results in this smaller set of patients with stroke followed the same pattern as in the full set. There were 11 discordant pairs, 9 of which had positive AF burden in the 30 days immediately preceding their stroke for an OR of 4.50 (95% CI, 0.931, 42.8). With the 3:1 matched analysis, the warfarin-adjusted OR was 4.51 (95% CI, 1.30, 20.1). The OR for days 1 to 5 immediately preceding the stroke was 27.0 (95% CI, 5.72-255), decreasing rapidly with 5-day intervals more separated in time from the event.
Discussion
From a VA population of ten thousand patients with CIEDs with atrial leads, we identified 187 patients with stroke and continuous measurement of daily AF burden for 120 days preceding the stroke event. As with similar previous studies, most patients had little to no evidence of AF, consistent with the fact that patients were not selected for the presence of AF. [22] [23] [24] But among those with clear evidence of AF, there was a strong association between AF burden ≥5.5 hours and short-term risk of ischemic stroke. The adjusted OR for stroke was 4.21 (95% CI, 1.53-13.44) using 3 control periods. Moreover, we found a strong relationship of temporal proximity of AF with ischemic stroke. The risk was highest in the 5 to 10 days after the episode of AF. By 30 days, the risk of stroke events was no longer elevated. This description of the temporal relationship of stroke risk is consistent with but extends the findings of the TRENDS study. 24 Our results are consistent with the hypothesis that relatively long episodes of AF confer a marked, but short-term increase in stroke risk. We dichotomized AF burden at 5.5 hours on any given day in the assessment period, applying the threshold found predictive of stroke in the TRENDS study. 24 It is clear from the current study and from results of the TRENDS study that the burden of AF preceding a stroke is often considerably higher than 5.5 hours on a single day. Indeed, 7 of our discordant cases had at least 1 day of continuous AF within the 30 days before the stroke event. However, our efforts to better define the dose-response of the amount of AF on any given day and stroke risk were not successful, largely because of the small number of discordant cases and because few of the discordant cases had short episodes of AF in the case period.
A recent publication from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing (ASSERT) study cast doubt on whether brief episodes of AF caused an acute increase in stroke risk. 22 The ASSERT investigators had previously postulated that even brief episodes of AF could result in a long-term prothrombotic left atrium. 8 The ASSERT study observed few events among individuals with any substantial frequency or duration of AF. We suspect that they were effectively observing a population without AF, making it difficult to assess the acute effects of AF on stroke risk.
Our study design cannot definitively address whether a transient episode of AF produces a small long-term increase in stroke risk, but our findings are clear that most of the stroke-promoting risk of a sizable episode of AF has dissipated by 4 weeks. Our findings suggest that transient use of rapidly acting anticoagulants linked to onset and offset of AF episodes could be a successful stroke-preventive strategy. Such a strategy deserves a definitive trial among patients with diagnosed paroxysmal or persistent AF, where the risk of stroke attributable to AF (and reversible by anticoagulants) would be high. The IMPACT trial attempted to test such a strategy in a largely non-AF population with ICD and cardiac resynchronization therapy-defibrillator devices. 25 However, the primary anticoagulant was warfarin, which has slow onset and offset of effect and a need for monitoring that fits poorly with a transient use design. Poor compliance with the intervention and low AF and outcome event rates prompted early stopping of the IMPACT trial on the basis of futility. 26 The core strength of our study is our large sample of patients with ischemic stroke, who had a continuous heart rhythm record for 120 days preceding the stroke event. However, only 16 of our 187 stroke cases were informative (ie, were discordant on AF burden using a threshold of 5.5 hours). Consequently, small sample size of informative patients remains a challenge. Prospective studies addressing this question would need to be large. Retrospective studies taking advantage of clinical records linked to continuous rhythm recording seem more practicable. Our case-crossover approach allowed efficient assessment of the AF burden/stroke relationship by limiting the analysis to patients with stroke. This design obviated the need for assembling separate control patients, a AF means ≥5.5 hours on any given day during the 30-day observation period. The case period is the 30-day period immediately preceding the patient's stroke. The control period is the selected 30-day observation period distant from the patient's stroke, here days 91 to 120 days pre stroke. The odds ratio for stroke, AF vs no AF, is calculated as the ratio of the discordant cells (*), here 13/3 or 4.33 (1.19-23.7) . The confidence interval and its calculation are described in the Results and Methods sections of this article, respectively. AF indicates atrial fibrillation.
Figure 2.
Daily atrial fibrillation (AF) burden over days 0 to 120 leading up to the patient's stroke. The vertical red line marks the day of the ischemic stroke. Vertical blue lines mark the end of the case period (day 30 before the stroke) and the beginning of the control period (day 91 before the stroke). A, Patients with discordant AF burden (defined as ≥5.5 h in any given day in the 30 d preceding the stroke) having a positive AF burden in the case period (days 1-30 pre stroke). B, Patients with discordant AF burden having a positive AF burden the control period (days 91-120 d pre stroke); C, A random sample of 10 concordantly negative patients. D, Patients concordant for a positive AF burden in both the case and the control periods.
process often subject to selection bias and residual confounding. The case-crossover approach was appropriate for the current study because our exposure of interest, AF burden, varied over short periods of time and its effect on outcome occurred rapidly and wore off quickly once the episode of AF ended.
There are several limitations to this study. First, stroke cases were ascertained from hospital claims. Although the ICD-9 algorithms used have been validated, it remains possible that some unclear neurological events were diagnosed as strokes because of the presence of AF. This concern is lessened by the fact that when we restricted the analysis to ICD-9 codes that are highly specific for ischemic stroke, our core findings were reproduced. Second, the cohort comprised Veteran patients, almost all of whom were men, thereby limiting generalizability. Third, because few pacemaker models during the observation period had daily AF diagnostics and transmitting capability, almost all devices in the cohort were ICDs. As such, these patients have a high burden of coronary or vascular disease and heart failure and are not representative of the average patient with AF. Testing of our analyses in cohorts more typical of AF populations, such as patients with pacemakers, implantable loop recorders, and even wearable continuous monitors, will determine whether our findings apply more broadly.
Conclusions
We studied 187 individuals with ischemic stroke who also had implanted cardiac devices providing 120 days of continuous heart rhythm monitoring immediately before the stroke event. The vast majority of these individuals had little to no AF throughout the observation period. However, focusing on the minority of patients who did have episodes of AF and using a case-crossover design, we found that AF burden of ≥5.5 hours in a given day raised the short-term risk of stroke 4-to 5-fold. This risk was highest in the initial 5 to 10 days after the episode of AF and rapidly declined after longer periods. Our findings indicate that the mechanism of stroke that applies to patients with more persistent AF also applies to populations with lower Figure 3 . Crude odds ratios for ischemic stroke with positive atrial fibrillation (AF) burden (≥5.5 h on any given day) for sequential nonoverlapping 5-d intervals from 1 to 5 d pre stroke (leftmost point) to 56-60 d pre stroke (right-most point). Each case period is matched to six 5-d control periods (91-95, 96-100, 101-105, 106-110, 111-115, and 116-120 d pre stroke). Adjacent table displays the point estimates and confidence intervals for these odds ratios.
burdens of AF detected by implanted devices. Our findings suggest that transient use of rapidly acting anticoagulants linked to onset and offset of AF episodes could be a successful strokepreventive strategy and merits a definitive randomized trial. 
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